Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CNCG vs HHS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HHS Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

HHS Overall Winner 6-Pillar Tally: CNCG 0 – 5 HHS (1 Tie) Matrix Metrics: CNCG 1 – 9 HHS

As of Nov 16, 2026, Harte Hanks, Inc. (HHS) is the stronger overall head-to-head candidate over CNCG (CNCG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CNCG carries a Unified Composite Score of 56.7/100 (HOLD) at $32.28 (N/M Forward P/E, N/A operating margin), whereas HHS carries 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CNCG vs HHS
CNCG US Equity
CNCG
Institutional Equity
$32.28
+0.59% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.32β · 78% Vol
Unified Composite Score
56.7 / 100 HOLD
Tech 40.0 Fund 48.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.8 · SMA20: $34.67 · SMA50: $32.46
HHS US Equity Head-to-Head Winner
Harte Hanks, Inc.
Services-Direct Mail Advertising Services
$3.84
-4.24% 1D
Market Cap $30.0M
TTM Revenue $155M
Forward P/E 14.3x
Beta / 30D Vol 0.49β · 46% Vol
Unified Composite Score
61.8 / 100 BUY
Tech 76.0 Fund 61.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 38.2 · SMA20: $3.95 · SMA50: $4.26

6-Pillar Scorecard Institutional Category Breakdown (CNCG 0 – 5 HHS)

Columns: Metric · CNCG · HHS
1. Valuation Multiples HHS
Forward P/E N/M 14.3x
Trailing P/E N/M 14.3x
PEG Ratio N/M 1.19x
EV / Revenue N/M 0.3x
2. Growth & Scale HHS
Revenue Growth (YoY) N/A -1.7%
Earnings Growth (YoY) N/A -90.3%
TTM Revenue (USD) N/A $155M
Market Cap N/A $30.0M
3. Profitability & Quality HHS
Gross Margin N/A 16.1%
Operating Margin N/A -3.2%
Net Profit Margin N/A -3.7%
Return on Equity (ROE) N/A -30.4%
4. Balance Sheet & Cash Flow HHS
Cash Generation (TTM) N/A -$4.5M
Cash Flow Margin N/A -2.9%
Net Cash / Leverage N/A ROE $17M Net Debt (1.10x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat HHS
OpEx & R&D Intensity N/A 19.3% of Rev ($30M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Conglomerates Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CNCG (1) vs HHS (9)
Institutional Metric CNCG HHS Criterion Row Edge
Market Capitalization
Scale
N/A $30.0M Larger Scale HHS
Trailing P/E Ratio
Valuation
N/M 14.3x Lower Multiple HHS
Forward P/E Ratio
Valuation
N/M 14.3x Lower Multiple HHS
Revenue Growth (YoY)
Growth
N/A -1.7% Higher Growth HHS
Operating Margin (TTM)
Profitability
N/A -3.2% Higher Margin HHS
Net Profit Margin
Profitability
N/A -3.7% Higher Margin HHS
Return on Equity (ROE)
Capital Efficiency
N/A -30.4% Higher ROE HHS
52-Week Range Position
Momentum
82% ($9–$38) 69% ($2–$5) Stronger Trend CNCG
Beta / 30D Volatility
Risk Regime
0.32β · 78% Vol 0.49β · 46% Vol Lower Realized Risk HHS
Unified Institutional Score
Composite Signal
56.7 / 100 (HOLD) 61.8 / 100 (BUY) Higher Composite HHS
Trailing 12M Revenue (USD)
Operating Scale
N/A $155M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 16.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.19x PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$4.5M ($17M Net Debt (1.10x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CNCG +10.11 pp
CNCG: +1.4% · HHS: -8.71%
3M Horizon CNCG +181.01 pp
CNCG: +157.13% · HHS: -23.88%
6M Horizon CNCG +74.97 pp
CNCG: +50.06% · HHS: -24.91%
1Y Horizon CNCG +143.34 pp
CNCG: +109.81% · HHS: -33.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNCG vs HHS. Trailing 12-month operating profitability (CNCG N/A vs HHS -3.2%) and valuation multiples (CNCG N/M vs HHS 14.3x Forward P/E) are benchmarked directly in Pillar 4 below.

CNCG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
HHS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$155M
Gross Margin16.1%
Op. Margin-3.2%
ROE / Fwd P/E-30.4% · 14.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CNCG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CNCG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HHS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact HHS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CNCG Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
HHS Moat Profile Cyclical / Execution-Driven Positioning
Conglomerates Operator
Competes within the Conglomerates value chain with $30.0M market capitalization and -3.2% operating margin.
OpEx & R&D Reinvestment 19.3% of Rev ($30M)
90D Engineering Disclosures 0 Published

Investor FAQ CNCG vs HHS Key Questions & Quantitative Answers

As of Nov 16, 2026, Harte Hanks, Inc. (HHS) is the stronger overall head-to-head candidate over CNCG (CNCG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CNCG carries a Unified Composite Score of 56.7/100 (HOLD) at $32.28 (N/M Forward P/E, N/A operating margin), whereas HHS carries 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin). Technically, CNCG sits in a Neutral phase (RSI 46.8, UNCLASSIFIED options structure) and HHS sits in a Neutral phase (RSI 38.2, UNCLASSIFIED options structure).

HHS leads the Growth & Scale pillar: CNCG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with HHS at -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin). On trailing 12-month operating scale, CNCG generates N/A in USD-normalized revenue versus $155M for HHS. In operating R&D and SG&A reinvestment, CNCG deploys N/A (0 90-day corporate R&D disclosures) versus 19.3% of Rev ($30M) (0 disclosures) for HHS.

HHS screens cheaper on headline valuation multiples. CNCG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNCG (N/A ROE) versus HHS (-30.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CNCG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 78% Vol realized risk). By comparison, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.